Answers are grounded in this paper and cite their sources.
Demonstrates immune tolerance induction in mice using an IL-2-TGF-β agonist, suggesting potential for treating immune-related diseases.
Introduction CD4+ regulatory T (Treg) cells are essential for immune tolerance. Peripherally induced Tregs (pTregs) complement thymic Tregs by broadening Treg reactivity in response to a changing antigenic landscape. Although both TGF-β and Interleukin-2 (IL-2) synergistically promote functional pTreg development in vitro, their combined roles in inducing pTreg generation in vivo are yet to be exploited for tolerizing immunotherapy. Methods We designed an IL-2-TGF-β “surrogate” co-agonist by creating a single-chain fusion protein between IL-2 and a low-affinity TGF-β mimic agonist derived from a Helminth parasite. This IL-2-TGF-β surrogate functions as an AND-gated co-agonist and enabled simultaneous cis-activation of both IL-2-STAT5 and TGF-β-SMAD2/3 signaling specifically in IL-2 receptor-expressing T cells. Results The IL-2-TGF-β surrogate agonist robustly induced antigen-specific, functional, and stable pTregs in vivo within peripheral lymphoid organs in OVA- or MOG35-55-immunized mice. The induced pTregs display an effector-like, actively expanding state with high Rorγt expression, enabling efficient migration and suppression of intestinal inflammation. Conclusion Treatment with this agonist effectively quelled immune activation in mouse models of allergen-induced allergic inflammation and self-antigen-driven autoimmune neuroinflammation, portending a strategy for the induction of antigen-specific pTregs in vivo to establish immune tolerance in inflammatory, allergic, and autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: